A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
| 适应症 | Dermatitis, Atopic |
|---|---|
| 分期 | 2期 |
| 申办方 | GlaxoSmithKline |
| 状态 | 提前终止 |
| 受试者人数 | 161 人 |
| 干预（药物） | GSK1070806 |
| 开始日期 | 2023年11月16日 |
| 完成日期 | 2025年7月23日 |
| 结果公布日 | 2026年6月3日 |
摘要
This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.
Percent Change From Baseline (CFB) in Eczema Area and Severity Index (EASI) Score at Week 16
| Placebo | -44.53 ± 40.805 Percent Change |
|---|---|
| GSK1070806 Dose Level 1 | -42.86 ± 36.186 Percent Change |
| GSK1070806 Dose Level 2 | -69.95 ± 33.363 Percent Change |
| GSK1070806 Dose Level 3 | -41.49 ± 43.341 Percent Change |
| GSK1070806 Dose Level 4 | -58.08 ± 33.129 Percent Change |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
- Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
- A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen